Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

1.77
Delayed Data
As of 4:00pm ET
 -0.12 / -6.35%
Today’s Change
1.75
Today|||52-Week Range
9.54
-26.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$101.9M

Company Description

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Contact Information

Corvus Pharmaceuticals, Inc.
863 Mitten Road
Burlingame California 94010
P:(650) 900-4520
Investor Relations:
(650) 900-4522

Employees

Shareholders

Individual stakeholders65.57%
Mutual fund holders6.29%
Other institutional35.23%

Top Executives

Richard A. MillerChairman, President & Chief Executive Officer
Leiv LeaChief Financial Officer
Gabriel LucianoVice President-Clinical Operations
Suresh MahabhashyamVice President-Clinical Development
Joseph J. BuggyExecutive Vice President-Discovery Research